Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass…
US, China Agree to Continue Talks on Tariff Truce Extension
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.Treasury Secretary Scott Bessent said that the US and China will continue talks over maintaining a tariff truce before it expires in two weeks and that President Donald Trump will make the final call on any extension.Bessent, who …
Compass Pathways: Independent Media Talks Psychedelic Medicine
In this episode of Divergent States, we sit down with Kabir Nath, CEO of Compass Pathways, and Dr. Steve Levine, Chief Patient Officer, to talk about the future of psychedelic medicine. From FDA approval and insurance coverage to patient access, cultural safety, and patents, we dig into whether Com…
Breaking New Ground with Psilocybin
In this episode, Brandon Li speaks with Kabir Nath, CEO of Compass Pathways, about their groundbreaking work in using psilocybin for treatment-resistant depression (TRD). Kabir shares his personal connection to mental health, the journey of Compass Pathways, and their rigorous approach to clinical …
CNS Summit Series: Can Psychedelics Reshape Psychiatry? A Conversation with Kabir Nath, CEO, Compass Pathways
Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients.
Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Hea…
New Hope for People Battling With Depression
Compass Pathways is a mental health care company developing new treatments for people who haven’t responded to existing medications and continue to struggle with their mental health. The company was the first to report successful Phase 3 clinical trial results for a psychedelic treatment, known as …
The Future of Psychedelic Medicine | Interview with Compass Pathways CEO Kabir Nath
Send us Fan Mail
Kabir Nath is Chief Executive Officer of Compass Pathways ( https://compasspathways.com/ ), a biotechnology company pioneering evidence-based psychedelic innovation for serious mental health conditions.Kabir brings nearly three decades of leadership experience across the biopharma…
FDA Engagement and the Evolving Psychedelic Therapy Landscape: A Conversation with Compass Pathways CEO Kabir Nath
Recorded on 03/03/26
TD Cowen senior biotech analyst Ritu Baral speaks with Compass CEO Kabir Nath at TD Cowen’s 46th Annual Health Care Conference. Discussion focused on FDA’s current approach to psychedelic drug development, what it signals for the broader psychiatry landscape, and the evolving …
Trump Aims to Seal Iran Deal, Says Truce Extension Unlikely
The people, companies and trends shaping the global economy.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
US President Donald Trump said he’s not likely to extend the two-week ceasefire with Iran, increasing the urgency for negotiators to conclude a deal to end the war.
…
S4, E5: Compass Pathways and the Quest to Bring Psychedelics to Psychiatry, with CEO Kabir Nath and Prof David Nutt
In this episode, Surani explores one of biotech’s most controversial and ambitious frontiers: psychedelic medicine.
At the center of the story is Compass Pathways, the London-based biotech attempting to bring synthetic psilocybin through the modern drug approval system for treatment-resistant dep…
ПОДКАСТ ТЪРСАЧКА
Можете да използвате нашия уебсайт, за да търсите3,821,551подкасти и195,365,154епизоди по хора, места или теми.
Инвестицията в знания носи най-добра доходност, затова слушам подкасти.
‐ Benjamin "Llamacorn" Franklin
РЕДАКТИРАНЕ
Благодарим Ви, че помогате да поддържаме базата данни за подкастове актуална.
